FY2024 EPS Estimates for Liquidia Boosted by HC Wainwright

Liquidia Co. (NASDAQ:LQDA) – Analysts at HC Wainwright lifted their FY2024 EPS estimates for shares of Liquidia in a report issued on Thursday, November 14th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($1.51) per share for the year, up from their previous forecast of ($1.54). HC Wainwright currently has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for Liquidia’s FY2025 earnings at ($1.62) EPS and FY2028 earnings at ($0.16) EPS.

A number of other equities research analysts have also recently commented on LQDA. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of Liquidia in a research report on Thursday, November 14th. Raymond James raised Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. Bank of America reduced their target price on Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. Lifesci Capital began coverage on Liquidia in a research report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price on the stock. Finally, Scotiabank assumed coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Liquidia Stock Performance

LQDA opened at $9.82 on Monday. The company has a fifty day moving average of $10.52 and a two-hundred day moving average of $11.47. The stock has a market capitalization of $831.14 million, a price-to-earnings ratio of -6.02 and a beta of 0.21. Liquidia has a fifty-two week low of $6.33 and a fifty-two week high of $16.99.

Hedge Funds Weigh In On Liquidia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quest Partners LLC acquired a new stake in shares of Liquidia in the 2nd quarter worth $27,000. Hilltop National Bank purchased a new stake in shares of Liquidia in the second quarter valued at about $33,000. Clear Harbor Asset Management LLC acquired a new stake in Liquidia during the third quarter worth about $100,000. Signaturefd LLC raised its stake in Liquidia by 38,400.0% during the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after purchasing an additional 9,984 shares during the period. Finally, Ballentine Partners LLC acquired a new position in Liquidia in the 3rd quarter valued at about $110,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Insider Activity at Liquidia

In related news, insider Rajeev Saggar sold 2,260 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now owns 207,383 shares of the company’s stock, valued at approximately $2,304,025.13. This represents a 1.08 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Caligan Partners Lp acquired 150,000 shares of the business’s stock in a transaction on Friday, August 30th. The stock was acquired at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the acquisition, the director now owns 6,994,997 shares in the company, valued at $66,522,421.47. The trade was a 2.19 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 21,551 shares of company stock valued at $236,021. 30.10% of the stock is owned by insiders.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).